Search
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. … [Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34.
Hydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. … Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.
Iodixanol
go.drugbank.com/drugs/DB01249ApprovedIodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736ApprovedAs part of the immune system, the thymus is an organ responsible for the maturation and selection of T cells [A239814]; thus, patients without a functional thymus experience profound immunodeficiency and … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.
Sacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalIt was approved by the FDA after being given the status of priority review for on July 7, 2015. … Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection
Terconazole
go.drugbank.com/drugs/DB00251Approved[A178093]Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole. … [A178096] Terconazole was initially approved by the FDA in 1987.
Products: FUNGISTAT OVULOS DE 80 MG., FUNGISTAT CREMA VAGINAL DE 0.8%Benzhydrocodone
go.drugbank.com/drugs/DB15465Approved[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Labetalol
go.drugbank.com/drugs/DB00598ApprovedInvestigationalLabetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. … [L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Categories: Adrenergic alpha-1 Receptor AntagonistsProducts: JOYALE-TAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalChemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer.
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]